Asahi Kasei Pharma Partners with MAIA for U.S. Teribone™ Development
- MAIA Pharmaceuticals will develop and commercialize Teribone™ in the U.S.
- Teribone™ is a treatment for osteoporosis, known generically as teriparatide acetate.
- Over 10 million in the U.S. are diagnosed with osteoporosis, with 44 million at risk.
- The collaboration aims to address the growing osteoporosis patient population in the U.S.
Partnership Overview
Asahi Kasei Pharma has partnered with MAIA Pharmaceuticals to develop and commercialize the osteoporosis drug Teribone™ in the United States. This collaboration leverages MAIA's regulatory, clinical, and development expertise in the U.S. market.
Drug Details
Teribone™, known generically as teriparatide acetate, is a treatment that promotes bone formation. It has been approved in Japan since 2011 and is available as a subcutaneous injection.
Market Context
In the U.S., over 10 million people are diagnosed with osteoporosis, and an estimated 44 million are at risk. The aging population is expected to increase the number of osteoporosis patients significantly, making it a critical medical and societal issue.
Strategic Goals
The collaboration aims to expand access to Teribone™ in the U.S., addressing the needs of a large and growing patient population at risk of fractures. This initiative aligns with Asahi Kasei's medium-term management plan, focusing on its Pharmaceuticals business as a priority area.
Source: Asahi Kasei